Although originally identified in a mouse model of BRCA1-mutant cancer [65], ABCB1 gene fusions that enhance activity have been observed in treatment-refractory breast and ovarian cancers, implying this could also be a cause of clinical PARPi resistance [66,67]. This evidence concerns the gene BRCA1 and cancer.